SEARCH



Transtox products CEO S Dravida has presented on “Stem Cell Based Platforms As Alternative Models – Use Cases In Drug Discovery, Development, Exploratory And Regulatory Toxicity Testing’s” in International workshop on “Translational Research Strategies for Drug Discovery and Clinical Development” that was conducted on 20th and 21st July 2019 at Hyderabad, India., Organized in collaboration withPharmaceuticals Export Promotion Council of India (Pharmexcil) and American Association of Precision Medicine (AAPM), USA.

The presentation covered:

  • Human sourced primary progenitor cellular platforms as invitro and meaningful predictive real time products for high throughput screening of chemical libraries
  • Identification of hits and lead optimization
  • Certain independent tests like: Mutagenicity, Tumorogenicity, Cytotoxicity, LD50, Molecular targets, Protein target identification and Drug repurposing
  • Certain complementary tests like: ADME, hepatotoxicity and cardiotoxicity
  • Highlighted the integration/adoption of right kind of pre-clinical models that are not traditional, but are modern and 100% close to human physiology, till regulatory testing’s for better prognosis of drug candidates in clinics


TranSTox products CEO S Dravida has presented on Stem Cell Based Platforms As Alternative Models – Use Cases In Drug Discovery, Development, Exploratory And Regulatory Toxicity Testings in International workshop on”Translational Research Strategies for Drug Discovery and Clinical Development” that was conducted on 20th and 21st July 2019 at Hyderabad, India., Organized in collaboration withPharmaceuticals Export Promotion Council of India (Pharmexcil), American Association of Precision Medicine (AAPM), USA.
The presentation covered: Human sourced primary progenitor cellular platforms as invitro and meaningful predictive real time products for high throughput screening of chemical libraries, identification of hits, lead optimization, Certain independent tests like: Mutagenicity, Tumorogenicity, Cytotoxicity, LD50, Molecular targets, Protein target identification, Drug repurposing, Certain complementary tests like: ADME, hepatotoxicity, cardiotoxicity.
Highlighting the integration/adoption of right kind of pre-clinical models that are not traditional, but are modern and 100% close to human physiology, till regulatory testings for better prognosis of drug candidates in clinics

Number of Views : 98 total views,  1 views today

Back to Top